SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...

Adding apalutamide to androgen deprivation therapy prolonged prostate-specific antigen progression-free survival in patients with biochemically recurrent prostate cancer in the phase 3 PRESTO trial.

A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients ...

In the article that accompanies this editorial, Aggarwal et al 8 found that 1 year of intensified androgen deprivation therapy (ADT) prolongs the time to next prostate-specific antigen progression (or ...

Longer time to relapse is associated with a decreased risk of dying from prostate cancer. PSA recurrence (PSAR) more than five years after radical prostatectomy for prostate cancer is associated with ...

Between 1995 and 2001, 206 men with localized but unfavorable-risk adenocarcinoma of the prostate were randomly assigned to receive RT or RT and AST, which was defined as 6 months of both a ...

ROCHESTER, Minn. — To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care necessary in the follow-up journey, Mayo Clinic’s Department ...

Editor's note: second of two parts; read part one here.. In the first part of our series, we described how PSA is used as a screening tool to help detect prostate cancer in men who don't have symptoms ...